• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2020 - 2060年中国全国范围内结直肠癌筛查策略的长期效益和成本效益评估:一项建模分析

Evaluation of long-term benefits and cost-effectiveness of nation-wide colorectal cancer screening strategies in China in 2020-2060: a modelling analysis.

作者信息

Lu Bin, Luo Jiahui, Yan Yike, Zhang Yuhan, Luo Chenyu, Li Na, Zhou Yueyang, Wu Dong, Dai Min, Chen Hongda

机构信息

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

出版信息

Lancet Reg Health West Pac. 2024 Aug 19;51:101172. doi: 10.1016/j.lanwpc.2024.101172. eCollection 2024 Oct.

DOI:10.1016/j.lanwpc.2024.101172
PMID:39247209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11380381/
Abstract

BACKGROUND

Evidence on the long-term benefits and cost-effectiveness of colorectal cancer (CRC) screening strategies in China remains limited. This modelling study aims to address this issue for various CRC screening strategies in China between 2020 and 2060.

METHODS

Using a previously developed microsimulation model (MIMIC-CRC) with Chinese epidemiological data, we evaluated four CRC screening strategies targeting population aged 45-74 years: no screening, colonoscopy every 10 years, biennial faecal immunochemical testing (FIT), and a roll-out FIT screening strategy. Screening coverage (invitation) rates from 5% to 100% were analysed. Single-cohort analysis of 100,000 individuals was conducted to estimate the relative cost-effectiveness of each strategy. A multiple-cohort analysis of 100,000 people aged 40+ over 2020-2060 was conducted to project nation-wide long-term benefits and cost-effectiveness.

FINDINGS

In single-cohort analysis, all strategies yielded reductions in CRC incidence and mortality compared to no screening, with colonoscopy outperforming FIT-based strategies at the same invitation rates. In multiple-cohort analysis, among people over 40 years of age in China over 2020-2060, compared to no screening, at invitation rate of 5%, screening by colonoscopy, biennial FIT and roll-out FIT-based approach were estimated to avert 1.2, 0.4, and 0.3 million incident CRCs and 0.2, 0.1, and 0.1 million CRC-related deaths, respectively, compared to no screening (25.4 million incident CRCs and 4.4 million CRC-related deaths), and this preventive effect enlarged as the screening coverage rate increased. At full coverage, colonoscopy achieved the largest reductions (38.2% lower incidence and 43.2% lower mortality) but required the most resources. Biennial FIT and roll-out FIT-based approach screening was slightly less effective but had significant reduced colonoscopy needs (reduction of 83.8% and 85.2%, respectively) and overall cost (reduction of 23.4% and 37.8%, respectively) compared to colonoscopy screening.

INTERPRETATION

Nation-wide implementation of screening would be effective in reducing the burden of CRC in China. Biennial FIT and roll-out FIT-based screening strategies could prevent incident CRC cases and CRC-related deaths with considerably fewer resources than colonoscopy screening. Efforts should be made to increase the screening coverage in China.

FUNDING

Chinese Academy of Medical Science Innovation Fund for Medical Science (2022-I2M-1-0031); National Natural Science Foundation of China (82173606; 82273726); Beijing Nova Program of Science and Technology (20230484397).

摘要

背景

中国结直肠癌(CRC)筛查策略的长期益处和成本效益方面的证据仍然有限。本建模研究旨在解决2020年至2060年间中国各种CRC筛查策略的这一问题。

方法

使用先前开发的带有中国流行病学数据的微观模拟模型(MIMIC-CRC),我们评估了针对45至74岁人群的四种CRC筛查策略:不筛查、每10年进行一次结肠镜检查、每两年进行一次粪便免疫化学检测(FIT)以及逐步推行FIT筛查策略。分析了5%至100%的筛查覆盖率(邀请率)。对100,000名个体进行单队列分析,以估计每种策略的相对成本效益。对2020年至2060年间100,000名40岁以上人群进行多队列分析,以预测全国范围内的长期益处和成本效益。

研究结果

在单队列分析中,与不筛查相比,所有策略均使CRC发病率和死亡率降低,在相同邀请率下,结肠镜检查优于基于FIT的策略。在多队列分析中,2020年至2060年间中国40岁以上人群中,与不筛查相比,在邀请率为5%时,结肠镜检查、每两年一次FIT和逐步推行基于FIT的方法筛查估计分别可避免120万、40万和30万例新发CRC以及20万、10万和10万例CRC相关死亡,而不筛查的情况下预计有2540万例新发CRC和440万例CRC相关死亡,并且随着筛查覆盖率的提高,这种预防效果会扩大。在全覆盖时,结肠镜检查实现的降低幅度最大(发病率降低38.2%,死亡率降低43.2%),但需要的资源最多。与结肠镜检查相比,每两年一次FIT和逐步推行基于FIT的方法筛查效果略差,但结肠镜检查需求显著减少(分别减少83.8%和85.2%),总体成本也显著降低(分别降低23.4%和37.8%)。

解读

在全国范围内实施筛查将有效减轻中国CRC的负担。每两年一次FIT和逐步推行基于FIT的筛查策略相比结肠镜检查筛查,可用更少的资源预防新发CRC病例和CRC相关死亡。应努力提高中国的筛查覆盖率。

资助

中国医学科学院医学科技创新基金(2022-I2M-1-0031);国家自然科学基金(82173606;82273726);北京市科技新星计划(20230484397)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/67c22feb28b3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/ab77071988f1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/491dc15f0d76/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/67c22feb28b3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/ab77071988f1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/491dc15f0d76/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7950/11380381/67c22feb28b3/gr3.jpg

相似文献

1
Evaluation of long-term benefits and cost-effectiveness of nation-wide colorectal cancer screening strategies in China in 2020-2060: a modelling analysis.2020 - 2060年中国全国范围内结直肠癌筛查策略的长期效益和成本效益评估:一项建模分析
Lancet Reg Health West Pac. 2024 Aug 19;51:101172. doi: 10.1016/j.lanwpc.2024.101172. eCollection 2024 Oct.
2
Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.结直肠癌混合筛查策略的健康获益和成本效益。
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1158-66. doi: 10.1016/j.cgh.2013.03.013. Epub 2013 Mar 28.
3
Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.用于结直肠癌筛查的粪便潜血试验:一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(10):1-40. Epub 2009 Sep 1.
4
Efficient organized colorectal cancer screening in Shenzhen: a microsimulation modelling study.深圳市高效有组织的结直肠癌筛查:一项微观模拟模型研究。
BMC Public Health. 2024 Mar 1;24(1):655. doi: 10.1186/s12889-024-18201-w.
5
6
Optimising colorectal cancer screening in Shanghai, China: a modelling study.优化中国上海结直肠癌筛查:模型研究。
BMJ Open. 2022 May 16;12(5):e048156. doi: 10.1136/bmjopen-2020-048156.
7
The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.45 岁及以上商业和医疗保险人群非侵入性基于粪便的结直肠癌筛查产品的成本效益。
J Med Econ. 2023 Jan-Dec;26(1):1219-1226. doi: 10.1080/13696998.2023.2260681. Epub 2023 Oct 6.
8
Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort study.在国家结直肠癌筛查项目中,采用粪便免疫化学检测和基于问卷的风险评估相结合的方法选择结肠镜筛查参与者:一项基于人群的队列研究。
PLoS Med. 2024 Feb 22;21(2):e1004340. doi: 10.1371/journal.pmed.1004340. eCollection 2024 Feb.
9
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers.粪便免疫化学试验筛查近端和远端结直肠癌的长期效果。
Gut. 2021 Dec;70(12):2321-2329. doi: 10.1136/gutjnl-2020-322545. Epub 2021 Jan 25.
10
Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.在低发国家进行结直肠癌筛查的成本效益分析:以沙特阿拉伯为例。
Saudi J Gastroenterol. 2021 Jul-Aug;27(4):208-216. doi: 10.4103/sjg.sjg_526_20.

引用本文的文献

1
Economic evaluations of scaling up strategies of evidence-based health interventions: a systematic review.扩大循证健康干预措施策略的经济评估:一项系统综述。
BMC Health Serv Res. 2025 Jul 1;25(1):836. doi: 10.1186/s12913-025-13024-w.
2
Multi-Omics-Based Analysis of the Effect of Longevity Genes on the Immune Relevance of Colorectal Cancer.基于多组学分析长寿基因对结直肠癌免疫相关性的影响
Biomedicines. 2025 Apr 30;13(5):1085. doi: 10.3390/biomedicines13051085.

本文引用的文献

1
Cancer incidence and mortality in China, 2022.2022年中国癌症发病率与死亡率
J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.
2
Cancer incidence and mortality in China, 2016.2016年中国癌症的发病率和死亡率
J Natl Cancer Cent. 2022 Feb 27;2(1):1-9. doi: 10.1016/j.jncc.2022.02.002. eCollection 2022 Mar.
3
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
4
Access to colorectal cancer screening in populations in China, 2020: A coverage-focused synthesis analysis.2020 年中国人群结直肠癌筛查的可及性:以覆盖面为重点的综合分析。
Int J Cancer. 2024 Aug 1;155(3):558-568. doi: 10.1002/ijc.34938. Epub 2024 Mar 30.
5
Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.基于满足医疗保险和医疗补助服务中心覆盖范围决策的血液检测进行结直肠癌筛查的效果和成本效益。
Gastroenterology. 2024 Jul;167(2):368-377. doi: 10.1053/j.gastro.2024.02.012. Epub 2024 Mar 26.
6
Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.基于血液生物标志物(液体活检)的结直肠癌筛查与粪便检测或结肠镜检查的比较有效性和成本效益。
Gastroenterology. 2024 Jul;167(2):378-391. doi: 10.1053/j.gastro.2024.03.011. Epub 2024 Mar 26.
7
Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN.全球、区域和国家层面在 185 个国家和地区终生罹患和死于胃肠道癌症的风险:基于人群的全球癌症负担系统分析。
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):229-237. doi: 10.1016/S2468-1253(23)00366-7. Epub 2024 Jan 4.
8
Cancer screening in China: a steep road from evidence to implementation.中国的癌症筛查:从证据到实施的艰难之路。
Lancet Public Health. 2023 Dec;8(12):e996-e1005. doi: 10.1016/S2468-2667(23)00186-X. Epub 2023 Nov 21.
9
An Evaluation of Critical Factors for the Cost-Effectiveness of Real-Time Computer-Aided Detection: Sensitivity and Threshold Analyses Using a Microsimulation Model.实时计算机辅助检测成本效益的关键因素评估:使用微模拟模型进行的敏感性和阈值分析。
Gastroenterology. 2023 May;164(6):906-920. doi: 10.1053/j.gastro.2023.01.027. Epub 2023 Feb 2.
10
Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.中国结直肠癌筛查中结肠镜检查和粪便免疫化学检测的成本效益分析。
Front Public Health. 2022 Aug 12;10:952378. doi: 10.3389/fpubh.2022.952378. eCollection 2022.